Myeloproliferative neoplasms by Jean-Jacques Kiladjian

Get full text

Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis by Léa Sureau, Corentin Orvain, Jean-Christophe Ianotto, Valérie Ugo, Jean-Jacques Kiladjian, Damien Luque Paz, Jérémie Riou

Get full text

PB2195: CHARACTERISTICS OF PATIENTS WITH POLYCYTHEMIA VERA: RESULTS FROM A US ELECTRONIC HEALTH RECORDS DATABASE. by Ronald Hoffman, Nishit Modi, Steffen Koschmieder, Francesco Passamonti, Nancy Reaven, Suneel Gupta, Arturo Molina, Jean-Jacques Kiladjian

Get full text

Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice by Shanti Amé, Fiorenza Barraco, Jean‐Christophe Ianotto, Eric Jourdan, Jérôme Rey, Jean‐François Viallard, Mathieu Wémeau, Jean‐Jacques Kiladjian

Get full text

Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms by Panhong Gou, Duanya Liu, Saravanan Ganesan, Evelyne Lauret, Nabih Maslah, Veronique Parietti, Wenchao Zhang, Véronique Meignin, Jean-Jacques Kiladjian, Bruno Cassinat, Stephane Giraudier

Get full text

ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis by Ralfs Buks, Mégane Brusson, Sylvie Cochet, Tatiana Galochkina, Bruno Cassinat, Ivan Nemazanyy, Thierry Peyrard, Jean-Jacques Kiladjian, Alexandre G. de Brevern, Slim Azouzi, Wassim El Nemer

Get full text

P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS by Jan Bewersdorf, Helen Ajufo, Claire Harrison, Francesca Palandri, John Mascarenhas, Jeanne Palmer, Aaron T. Gerds, Jean-Jacques Kiladjian, Andrii Derkach, Karisse Roman-Torres, Sarah Buckley, Raajit K Rampal

Get full text

Altered Ca²⁺ Homeostasis in Red Blood Cells of Polycythemia Vera Patients Following Disturbed Organelle Sorting during Terminal Erythropoiesis by Ralfs Buks, Tracy Dagher, Maria Giustina Rotordam, David Monedero Alonso, Sylvie Cochet, Emilie-Fleur Gautier, Philippe Chafey, Bruno Cassinat, Jean-Jacques Kiladjian, Nadine Becker, Isabelle Plo, Stéphane Egée, Wassim El Nemer

Get full text

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS by Marina Kremyanskaya, Claire Harrison, Prithviraj Bose, Vikas Gupta, Raajit K Rampal, Jonathan Lambert, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Sandra Klein, Carmelita Alvero, John Mascarenhas

Get full text

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis by Claire Harrison, Florian H. Heidel, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Amjad Hayat, Francesco Passamonti, Eibhlin Conneally, Thomas Kindler, Bruno Martino, Daniel B. Lipka, Tommaso Stefanelli, Pantelia Roussou, Davide Germano, Jacqueline Ewan, Vincent Ribrag

Get full text

Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project by Srdan Verstovsek, Ivan Krečak, Florian H. Heidel, Valerio De Stefano, Kenneth Bryan, Mike W. Zuurman, Michael Zaiac, Mara Morelli, Aoife Smyth, Santiago Redondo, Erwan Bigan, Michael Ruhl, Christoph Meier, Magali Beffy, Jean-Jacques Kiladjian

Get full text

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Plac... by Ruben A. Mesa, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Shelonitda Rose, Pranav Abraham, Jennifer Lord-Bessen, Derek Tang, Shien Guo, Xiaomei Ye, Claire N. Harrison

Get full text

PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF) by John Mascarenhas, Claire Harrison, Jean-Jacques Kiladjian, Katja Sockel, Alessandro Vannucchi, Tymara Berry, Denise Redding, Laurie Sherman, Souria Dougherty, Lixian Peng, Libo Sun, Fei Huang, Ying Wan, Vivian Rodolf, Judy Ho, Shyamala Navada, Rami S. Komrokji

Get full text

P1022: PHASE 1/2 STUDY OF THE ACTIVIN RECEPTOR-LIKE KINASE 2 (ALK2) INHIBITOR ZILURGISERTIB (INCB000928, LIMBER-104) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE... by Prithviraj Bose, Sanjay Mohan, Stephen Oh, Jason Gotlib, Ellen Ritchie, Taizo Shimomura, Haris Ali, Francoise Boyer, Paola Guglielmelli, Anthony M. Hunter, Betty Lamothe, Yi Cui, Francis Seguy, Amanda Mcbride, Francesca Palandri, Masahiro Takeuchi, Jean-Jacques Kiladjian

Get full text

P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA by Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian

Get full text

P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS by Claire Harrison, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Raajit K Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Soumik Dutta, Sandra Klein, Jie Cui, Tzuu-Wang Chang, John Mascarenhas

Get full text

S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (... by Pankit Vachhani, Andrew Perkins, John Mascarenhas, Haifa Kathrin Al-Ali, Jean-Jacques Kiladjian, Sonia Cerquozzi, Jaroslaw Dybko, Regina Garcia Delgado, Jesus Hernández Rivas, Holger Hebart, Zhuying Huang, Cecile Krejsa, Hope Qamoos, Jesse Mcgreivy, Wayne P. Rothbaum, Srdan Verstovsek, Alessandro Vannucchi

Get full text

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups by Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Viktor Rossiev, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian, for the PROUD-PV Study Group

Get full text

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET by Kai Wille, Maja Brouka, Johannes Bernhardt, Axel Rüfer, Emilia Niculescu-Mizil, Mirjana Gotic, Susanne Isfort, Steffen Koschmieder, Tiziano Barbui, Parvis Sadjadian, Tatjana Becker, Vera Kolatzki, Raphael Meixner, Hannah Marchi, Christiane Fuchs, Frank Stegelmann, Konstanze Döhner, Jean-Jacques Kiladjian, Martin Griesshammer

Get full text

S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY by Aaron T. Gerds, Claire Harrison, Jean-Jacques Kiladjian, Ruben Mesa, Alessandro Vannucchi, Rami S. Komrokji, Prithviraj Bose, Marina Kremyanskaya, Adam Mead, Jason Gotlib, Fabian Sanabria, Niloufar Marsousi, Ana Carolina Giuseppi, Huijing Jiang, Jeanne Palmer, Kelly Mccaul, Vincent Ribrag, Srdan Verstovsek, Francesco Passamonti

Get full text